3654 results for «600»
3654 results
Complication one: PCI complications occuring during urgent PCI for NSTEMI
20 May 2026 – From EuroPCR 2026
Examine real-world PCI complications encountered during urgent interventions for NSTEMI patients. This session presents a series of complex cases illustrating management strategies for adverse events such as coronary perforations, device issues, and imaging challenges to inform safer procedural practice.
Complex patients with NSTEMI
20 May 2026 – From EuroPCR 2026
This session addresses the complexity of managing NSTEMI patients with challenging clinical presentations, including concurrent vessel and valve disease, thrombus burden, and atypical angiographic findings. It offers practical strategies for diagnosis and intervention to optimize patient outcomes.
Atypical STEMI presentations
20 May 2026 – From EuroPCR 2026
Investigate atypical presentations of STEMI and the unique challenges they pose in clinical management. This session covers case studies including high bleeding risk patients, mechanical complications post-surgery, spontaneous coronary artery dissection, and recurrent events, emphasizing tailored therapeutic approaches.
TTVR: novel techniques and new horizons
20 May 2026 – From EuroPCR 2026
Explore novel techniques and emerging technologies in transcatheter tricuspid valve replacement (TTVR). This session showcases innovative devices and approaches, early clinical experiences, and strategies to address challenges such as pacemaker leads and failed tricuspid TEER procedures.
Mitral valve-in-valve, valve-in-ring, valve-in-mac: the good, the bad and the ugly
20 May 2026 – From EuroPCR 2026
This session delves into the complexities of mitral valve interventions, focusing on valve-in-valve, valve-in-ring, and valve-in-mitral annular calcification (MAC) procedures. It addresses troubleshooting in high-risk valve-in-MAC cases, urgent transcatheter mitral valve implantation supported by microaxial flow pumps, challenges in delivering balloon expandable valves transeptally, and innovative...
Cardiogenic shock: identifying the cause and tailoring the treatment
20 May 2026 – From EuroPCR 2026
This session focuses on the critical evaluation and management of cardiogenic shock by identifying its underlying causes and tailoring treatment accordingly. It presents complex cases including free wall rupture bail-out strategies, management dilemmas in inferior STEMI complicated by incomplete ventricular rupture, multifactorial culprit lesions, refractory hypotension...
CTO PCI in images and case examples: what is new in 2026?
07 Jul 2026
Register for free to this webinar on Monday 31 August at 6:00pm with K. Mashayekhi, M. Ayoub and C. Ungureanu and learn to review the recent evidence on expected outcomes after CTO PCI, and much more!
Primary Outcomes of a Pivotal Multicenter Randomized Trial Comparing the AGENT Paclitaxel-Coated Ballon with Conventional Ballon Angioplasty for In-Stent Restenosis (AGENT IDE)
27 Oct 2023
Mirvat Alasnag provides her take on the AGENT IDE trial which was presented by Robert W. Yeh at TCT Congress 2023. This pivotal randomized trial compares the safety and efficacy of the AGENT DCB to conventional balloon angioplasty in patients with ISR. It is the first...
Author
The greatest advance in the next 40 years would be to remove the need for angioplasty
17 May 2017
Spencer B. King performed some of the first coronary angioplasty procedures in the USA—having recently received a thank-you from the first patient that he treated. He tells The Daily Wire that the steerable guidewire, rather than the stent, was the greatest advance in angioplasty and that...
Authors :
ALL-RISE: A large-scale, global randomized trial of coronary physiology derived from conventional angiography compared with an invasive pressure wire-based approach to guide PCI
28 Mar 2026
Mirvat Al Asnag provides her take on the ALL-RISE randomised trial presented by Ajay J. Kirtane at ACC.26 in New Orleans.
Author
From PROTECT-AF to CHAMPION-AF: Where do we stand today?
01 Jul 2026
In this article, Jens Erik Nielsen-Kudsk reviews the evolution of left atrial appendage closure, from early trials such as PROTECT‑AF to recent evidence including CHAMPION‑AF, and discusses its expanding role in stroke prevention for atrial fibrillation.
Author
A randomized, placebo-controlled trial of chronic total occlusion PCI in stable angina - ORBITA-CTO trial
03 Apr 2026
Kalaivani Mahadevan provides an in-depth analysis of the ORBITA-CTO trial: a first-ever randomised, double-blind, placebo-controlled trial evaluating CTO PCI in stable angina patients.
She also interviewed principal investigators Sarosh Khan and John Davies following the LBCT Scientific Session at ACC.26 in New Orleans and simultaneous publication in...
Author
Author
Author
The AQUATIC trial: Assessment of quitting versus using aspirin therapy in patients with stabilized coronary artery disease after stenting who require long-term oral anticoagulation
01 Sep 2025
Chiara De Biase provides her take on the results of AQUATIC presented by Martine Gilard at ESC Congress 2025 in Madrid.
Author
![The AQUATIC trial [Assessment of quitting versus using aspirin therapy in patients with stabilized coronary artery disease after stenting who require long-term oral anticoagulation: Rationale for and design of the AQUATIC double-blind randomized trial]](https://www.pcronline.com/var/pcrov3/storage/images/pcronline/news/congress-coverages/esc/2025/aquatic-trial-quitting-versus-using-aspirin-therapy-patients-stabilized-cad-stenting-long-term-oral-anticoagulation/27448089-9-eng-GB/The-AQUATIC-trial-Assessment-of-quitting-versus-using-aspirin-therapy-in-patients-with-stabilized-coronary-artery-disease-after-stenting-who-requi_image_responsive_6.jpg)
COVID-19 vaccines: Burning questions from the community and real-world applicability
13 Jan 2021
View a number of questions of interest to the interventional cardiovascular community, as well as the real-world applicability of COVID-19 vaccine trials.
